Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Brooks Boyd"'
Autor:
Parthena Martin, Maciej Czerwiński, Pallavi B. Limaye, Seema Muranjan, Brian W. Ogilvie, Steven Smith, Brooks Boyd
Publikováno v:
Pharmacology Research & Perspectives, Vol 10, Iss 3, Pp n/a-n/a (2022)
Abstract Fenfluramine (FFA) has potent antiseizure activity in severe, pharmacoresistant childhood‐onset developmental and epileptic encephalopathies (e.g., Dravet syndrome). To assess risk of drug interaction affecting pharmacokinetics of FFA and
Externí odkaz:
https://doaj.org/article/04df080337a2488487b752ec4dbe020f
Autor:
Parthena Martin, Maciej Czerwiński, Pallavi B. Limaye, Brian W. Ogilvie, Steven Smith, Brooks Boyd
Publikováno v:
Pharmacology Research & Perspectives, Vol 10, Iss 3, Pp n/a-n/a (2022)
Abstract Studies support the safety and efficacy of fenfluramine (FFA) as an antiseizure medication (ASM) in Dravet syndrome, Lennox‐Gastaut syndrome, or CDKL5 deficiency disorder, all pharmacoresistant developmental and epileptic encephalopathies.
Externí odkaz:
https://doaj.org/article/e9e24215cd6d45aaa822e276f79563c2
Publikováno v:
Epilepsybehavior : EB. 127
Fenfluramine (N-ethyl-α-methl-3-(trifluoromethyl)phenethylamine) is an anti-seizure medication (ASM) particularly effective in patients with Dravet syndrome, a severe treatment-resistant epileptic encephalopathy. Fenfluramine acts not only as neuron
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::074f016012f72fcea98b3abc438f4845
https://pubmed.ncbi.nlm.nih.gov/35007961
https://pubmed.ncbi.nlm.nih.gov/35007961
Publikováno v:
Pharmaceutical Research; Oct2004, Vol. 21 Issue 10, p1776-1782, 7p
Autor:
BROOKS, BOYD S.
Publikováno v:
Journal of the American Concrete Institute; Jan1949, Vol. 45, p369-380-7, 19p